Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C5H12N2O3S |
| Molecular Weight | 180.225 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[S+]([O-])(=N)CC[C@H](N)C(O)=O
InChI
InChIKey=QLMUQBNMEHYOAX-DPVSGNNYSA-N
InChI=1S/C5H12N2O3S/c1-11(7,10)3-2-4(6)5(8)9/h4H,2-3,6H2,1H3,(H2-,7,8,9,10)/t4-,11?/m0/s1
| Molecular Formula | C5H12N2O3S |
| Molecular Weight | 180.225 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
L-METHIONINE-S,R-SULFOXIMINE is a convulsant, although the susceptibility to convulsions induced by this compound depends on the species, and primates are relatively resistant. It is a methionine sulfoximine in which the amino group has S-stereochemistry. It has a role as an EC 6.3.1.2 (glutamate--ammonia ligase) inhibitor.
Sub-convulsive doses of L-METHIONINE-S,R-SULFOXIMINE are neuroprotective in rodent models of hyperammonemia, acute liver disease, and amyotrophic lateral sclerosis and suggest L-METHIONINE-S,R-SULFOXIMINE may be clinically useful. Studies have also indicated that L-METHIONINE-S,R-SULFOXIMINE is therapeutic in the treatment of glutamate excitotoxicity.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:01:45 UTC 2023
by
admin
on
Sat Dec 16 08:01:45 UTC 2023
|
| Record UNII |
M9P6YZ6JX9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
M9P6YZ6JX9
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
Methionine sulfoximine
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
87826
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
47833
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
DTXSID30936181
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
89034
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
28490
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
1722382
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | RxNorm | ||
|
15985-39-4
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY | |||
|
M9P6YZ6JX9
Created by
admin on Sat Dec 16 08:01:45 UTC 2023 , Edited by admin on Sat Dec 16 08:01:45 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ENANTIOMER -> RACEMATE |
|
||
|
ENANTIOMER -> RACEMATE |
|
